Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Post by sjaakon Mar 16, 2003 10:02am
302 Views
Post# 5950293

calgary herald article

calgary herald articleI am getting the impression that ONC has shut down its investor relations function. We used to see a lot of posts about discussions with Brad Thompson from time to time and those don't appear anymmore. Dr. Thompson's approach, if correctly quoted in the Herald seem to be that when the company has some news he will provide it, however there does not seem to be any quidance from ONC about what is currently happening and what some realistic timelines might be for release of prostate results or commencement of the glio trials. While I do not attribute any need to be concerned about the lack of news from ONC, I do find it frustrating that they have not disclosed much information recently and leave their shareholders in the dark about the timing of future events. In all fairness to ONC I have not called them and have been relying on this board for my information. I have held ONC shares for more than 2 years and have followed their progress diligently as I hold a fairly significant position. One thing I have never been able to understand is why Dr. Lee is no longer involved with the company as he was instrumental in developing resolin. I have seen Dr. Lee speak before he departed and his enthusiasm and apparent integrity made an impression on me. Finally I certainly miss the posts of Bioeye although I can understand if she doesn't wish to contribute to this board since while there a still a number of excellant contributors there is a new group of posters who seem to peoccupied by focussing on negative and personal issues.
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse